A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin XR Tablet (2 x 500 mg) in Healthy Fed Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2014
Price : $35 *
At a glance
- Drugs Canagliflozin/metformin (Primary) ; Canagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 16 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
- 12 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.
- 27 Feb 2014 New trial record